These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 23724492)
41. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. Ridker PM; Cook NR; Lee IM; Gordon D; Gaziano JM; Manson JE; Hennekens CH; Buring JE N Engl J Med; 2005 Mar; 352(13):1293-304. PubMed ID: 15753114 [TBL] [Abstract][Full Text] [Related]
42. Direct Oral Anticoagulants in Addition to Antiplatelet Therapy for Secondary Prevention after Acute Coronary Syndromes: a Review. Khalil P; Kabbach G Curr Cardiol Rep; 2019 Jan; 21(1):5. PubMed ID: 30689068 [TBL] [Abstract][Full Text] [Related]
43. Improvement of low-density lipoprotein cholesterol target achievement rates through cardiac rehabilitation for patients after ST elevation myocardial infarction or non-ST elevation myocardial infarction in Germany: Results of the PATIENT CARE registry. Schwaab B; Zeymer U; Jannowitz C; Pittrow D; Gitt A Eur J Prev Cardiol; 2019 Feb; 26(3):249-258. PubMed ID: 30509144 [TBL] [Abstract][Full Text] [Related]
44. Participation in disease management programs and major adverse cardiac events in patients after acute myocardial infarction: a longitudinal study based on registry data. Fischer C; Höpner J; Hartwig S; Noutsias M; Mikolajczyk R BMC Cardiovasc Disord; 2021 Jan; 21(1):18. PubMed ID: 33407174 [TBL] [Abstract][Full Text] [Related]
45. Antiplatelet treatment in the secondary prevention of coronary and cerebrovascular disease: is there any place for novel agents? Ntalas IV; Milionis HJ; Kei AA; Kalantzi KI; Goudevenos JA Angiology; 2014 Jul; 65(6):473-90. PubMed ID: 23966569 [TBL] [Abstract][Full Text] [Related]
46. Physical activity in the cardiac patient. Sellier P J Cardiovasc Pharmacol; 1995; 25 Suppl 1():S9-14. PubMed ID: 7752669 [TBL] [Abstract][Full Text] [Related]
47. [Antithrombotic therapy after myocardial infarction: arguments for the use of acetylsalicylic acid and coumarin derivatives]. Waskowsky WM; Brouwer A; Verheugt FW Ned Tijdschr Geneeskd; 2005 Jan; 149(2):65-71. PubMed ID: 15688836 [TBL] [Abstract][Full Text] [Related]
48. Rehabilitation after myocardial infarction trial (RAMIT): multi-centre randomised controlled trial of comprehensive cardiac rehabilitation in patients following acute myocardial infarction. West RR; Jones DA; Henderson AH Heart; 2012 Apr; 98(8):637-44. PubMed ID: 22194152 [TBL] [Abstract][Full Text] [Related]
49. The follow-up after myocardial infarction - is it good enough? Munkhaugen J; Peersen K; Sverre E; Gjertsen E; Gullestad L; Dammen T; Husebye E; Otterstad JE Tidsskr Nor Laegeforen; 2018 Mar; 138(5):. PubMed ID: 29513442 [No Abstract] [Full Text] [Related]
50. The cardiac model of rehabilitation for reducing cardiovascular risk factors post transient ischaemic attack and stroke: a randomized controlled trial. Kirk H; Kersten P; Crawford P; Keens A; Ashburn A; Conway J Clin Rehabil; 2014 Apr; 28(4):339-49. PubMed ID: 24121497 [TBL] [Abstract][Full Text] [Related]
56. Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome. Arca M Drugs; 2007; 67 Suppl 1():43-54. PubMed ID: 17910520 [TBL] [Abstract][Full Text] [Related]
57. Diabetes: can we stop the time bomb? Fisher M Heart; 2003 May; 89 Suppl 2(Suppl 2):ii28-30; discussion ii35-7. PubMed ID: 12695433 [TBL] [Abstract][Full Text] [Related]
58. Management of stroke risk factors during the process of rehabilitation. Secondary stroke prevention. Halar EM Phys Med Rehabil Clin N Am; 1999 Nov; 10(4):839-56, viii. PubMed ID: 10573711 [TBL] [Abstract][Full Text] [Related]